Updated consensus statement: Intravenous immunoglobulin in the treatment of neuromuscular disorders report of the AANEM ad hoc committee.

Abstract

Intravenous immune globulin (IVIG) is an immune-modulating biologic therapy that is increasingly being used in neuromuscular disorders despite the paucity of high-quality evidence for various specific diseases. To address this, the AANEM created the 2009 consensus statement to provide guidance on the use of IVIG in neuromuscular disorders. Since then, there have been several randomized controlled trials for IVIG, a new FDA-approved indication for dermatomyositis and a revised classification system for myositis, prompting the AANEM to convene an ad hoc panel to update the existing guidelines.New recommendations based on an updated systemic review of the literature were categorized as Class I-IV. Based on Class I evidence, IVIG is recommended in the treatment of chronic inflammatory demyelinating polyneuropathy, Guillain-Barré Syndrome (GBS) in adults, multifocal motor neuropathy, dermatomyositis, stiff-person syndrome and myasthenia gravis exacerbations but not stable disease. Based on Class II evidence, IVIG is also recommended for Lambert-Eaton myasthenic syndrome and pediatric GBS. In contrast, based on Class I evidence, IVIG is not recommended for inclusion body myositis, post-polio syndrome, IgM paraproteinemic neuropathy and small fiber neuropathy that is idiopathic or associated with tri-sulfated heparin disaccharide or fibroblast growth factor receptor-3 autoantibodies. Although only Class IV evidence exists for IVIG use in necrotizing autoimmune myopathy, it should be considered for anti-hydroxy-3-methyl-glutaryl-coenzyme A reductase myositis given the risk of long-term disability. Insufficient evidence exists for the use of IVIG in Miller-Fisher syndrome, IgG and IgA paraproteinemic neuropathy, autonomic neuropathy, chronic autoimmune neuropathy, polymyositis, idiopathic brachial plexopathy and diabetic lumbosacral radiculoplexopathy.

• Authors: Jinny Tavee, Thomas H Brannagan 3rd, Michael W Lenihan, Sri Muppidi, Liz Kellermeyer, Peter D Donofrio, AANEM
• Journal: Muscle & nerve (Muscle Nerve) Vol. 68 Issue 4 Pg. 356-374 (10 2023) ISSN: 1097-4598 [Electronic] United States
• PMID: 37432872 (Publication Type: Review, Journal Article)
• Copyright: Copyright © 2023 by the American Association of Neuromuscular & Electrodiagnostic Medicine, Inc. All rights reserved.

Chemical References

• Immunoglobulins, Intravenous

Topics

• Humans
• Child
• Immunoglobulins, Intravenous (therapeutic use)
• Dermatomyositis
• Neuromuscular Diseases (therapy)
• Myasthenia Gravis (therapy)
• Guillain-Barre Syndrome
• Myositis
• Polyneuropathies
• Myositis, Inclusion Body